Sobi Names Carol Satler, M.D., Ph.D., Vice President, Medical Affairs, North America

WALTHAM, Mass.--(BUSINESS WIRE)-- Sobi, an international biopharmaceutical company dedicated to rare diseases, announced today that Carol Satler, M.D., Ph.D., has joined the company as the Vice President of Medical Affairs in North America.

Satler has more than 25 years of experience in the healthcare industry spanning roles in medical affairs, clinical research and clinical practice as a pediatrician and pediatric cardiologist. She most recently served as the Vice President & Therapeutic Area Head, Cardiovascular Clinical Research at Gilead Sciences, Inc., where she worked on clinical development and launch planning for multiple rare disease products. Prior to that she was Vice President of U.S. Medical Affairs, General Medicine at Bayer Healthcare Pharmaceuticals, Inc.; and Vice President and Head, North America Medical Affairs at UCB, Inc. She previously held medical and clinical roles at Millennium Pharmaceuticals, Inc.; Forest Research Institute, Inc.; Sanofi; and Pfizer, Inc.; and she served as President and Chief Executive Officer at Indigo Pharmaceuticals, Inc. Satler trained and served on the faculty at Harvard Medical School and Boston Children’s Hospital in Medicine, Pediatrics and Pediatric Cardiology for over a decade. She earned her M.D.-Ph.D. from Case Western Reserve University and her B.A. in Chemistry from Wesleyan University.

“Carol’s experience leading clinical and medical teams will be critical as Sobi continues to tap into both internal and external sources of innovation to expand our development pipeline and our portfolio of marketed products,” said Rami Levin, President of Sobi in North America. “Additionally, her training as a pediatrician and her extensive experience in rare diseases are an excellent fit with Sobi’s vision to become a global leader in treating rare diseases.”

“I look forward to applying my skillset as a physician executive to support Sobi’s clinical programs, new product launches and established products across multiple rare disease indications,” said Satler. “There is tremendous unmet need in the rare disease space, which I have witnessed firsthand as a pediatrician, and I am excited to join the Sobi team in pursuing solutions.”

About Sobi in North America
As the North American affiliate of international biopharmaceutical company Sobi™, our team is committed to Sobi’s vision of providing access to innovative treatments that make a significant difference in the lives of individuals with rare diseases. Our product portfolio includes multiple approved treatments, focused on inflammation and genetics/metabolism. With North American headquarters in the Boston area, Canadian headquarters in the Toronto area, and field sales, medical and market access representatives spanning North America, our growing team has a proven track record of commercial excellence. More information is available at www.sobi-northamerica.com. For more information about Sobi, visit www.sobi.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181009005353/en/